Product Details
PT-141, also known as Bremelanotide, is a synthetic peptide derived from the melanocortin family of compounds. It is primarily known for its interaction with melanocortin receptors in the central nervous system, particularly pathways associated with sexual desire and arousal. How PT-141 Works Unlike medications that primarily influence vascular blood flow, PT-141 works through central nervous system signaling. It activates melanocortin receptors, including MC4R, which are involved in neurological pathways associated with sexual motivation and response. Because of this distinct mechanism, PT-141 has been studied for its potential effects on sexual-response signaling in both females and males. Areas of Research Interest Research involving PT-141 and the melanocortin system has included: * Sexual desire and arousal — Studied for its effects on neurological pathways involved in sexual motivation and response. * Melanocortin receptor activity — Used to investigate how melanocortin receptors influence behavioral and physiological processes. * Central nervous system signaling — Research examines how activation of specific melanocortin receptors affects brain-mediated responses. * Female sexual-response research — Bremelanotide has undergone clinical research involving premenopausal women experiencing certain disorders of sexual desire. * Male sexual-response research — Earlier studies also investigated melanocortin signaling and erectile responses in men. PT-141 vs. Traditional ED Medications PT-141 has a fundamentally different mechanism from medications such as sildenafil (Viagra) or tadalafil (Cialis). Those medications primarily work through the PDE5 pathway to enhance blood flow, whereas PT-141 acts through melanocortin receptors in the brain. This distinction has made PT-141 particularly interesting in research focused on centrally mediated sexual desire and arousal. Important Regulatory Distinction Bremelanotide is the active ingredient in the FDA-approved prescription medication Vyleesi®, which is approved for a specific indication involving acquired, generalized hypoactive sexual desire disorder (HSDD) in certain premenopausal women. However, a vial marketed and sold as “PT-141 10mg — for research use only” is not the same thing as an FDA-approved Vyleesi prescription product and should not be represented as an approved medication or treatment. Add this section to the PT-141 description: Half-Life & Pharmacokinetics PT-141 (Bremelanotide) has a mean terminal half-life of approximately 2.7 hours, with a reported range of approximately 1.9–4.0 hours following subcutaneous administration. (FDA Access Data) Its median Tmax (time to reach peak plasma concentration) is approximately 1 hour. As a seven-amino-acid peptide, Bremelanotide is primarily metabolized through hydrolysis of its peptide bonds. (FDA Access Data) Half-Life: ~2.7 hours Reported range: 1.9–4.0 hours Tmax: ~1 hour For research and educational purposes only. Not intended for human consumption or for the diagnosis, treatment, cure, or prevention of disease.